Skip to main content

Advertisement

Table 3 A full factorial model of ANCOVA to adjust the possible effect of anti-diabetic and anti-hypertensive drugs on circulating levels of CTRP5 in controls, NAFLD, T2DM and NAFLD + T2DM patients

From: The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study

Status Status Mean difference (I − J) ± SEM p value 95 % confidence interval for difference
Lower bound Upper bound
Control NAFLD 40.208 ± 3.164 0.000 31.657 48.759
T2DM 45.197 ± 3.338 0.000 36.176 54.219
NAFLD + T2DM 42.926 ± 3.293 0.000 34.028 51.824
  1. NAFLD non-alcoholic fatty liver disease, T2DM type 2 diabetes mellitus, CTRP5 complement-C1q TNF-related protein 5, SEM standard error of mean